Daliya Pencheva
Daliya Pencheva is a rheumatologist at the Clinic of Rheumatology, University Hospital “St. Ivan Rilski”, Sofia, Bulgaria. She obtained her PhD from the Medical University of Sofia with a research focus on the management of systemic lupus erythematosus (SLE). Her main interests include patient-reported outcome measures, quality of life, and treat-to-target strategies in rheumatic diseases. Daliya has been actively involved in subcommittee activities for the past three years and currently serves as the EMEUNET Country Liaison for Bulgaria.
| Oral OP0219 | Thursday, 4 June 2026, 8:25 – 8:35 BST Clinical Abstract Sessions: DORIS and the wolf – outcome measures in SLE Author: M Mosca (Italy) Title: DORIS REMISSION AND LLDAS ATTAINMENT AFTER UP TO 12 MONTHS OF REAL-WORLD ANIFROLUMAB TREATMENT: INTERIM RESULTS FROM THE ASTER STUDY  This interim analysis from the multinational ASTER real-world study evaluated DORIS remission and Lupus Low Disease Activity State (LLDAS) attainment in 530 patients with SLE treated with anifrolumab. Treatment was associated with substantial improvements in disease activity, including a mean reduction of 4.6 points in SLEDAI-2K, achievement of a SLEDAI-2K score of 0 in 29.3% of patients at 12 months, and marked reductions across multiple organ systems, supporting the effectiveness of a treat-to-target approach in routine clinical practice. |
| Oral OP0222 | Thursday, 4 June 2026, 08:55 – 09:05 BST Clinical Abstract Sessions: DORIS and the wolf – outcome measures in SLE Author: I Parodis (Sweden) Title: PROTEINURIA UNDERESTIMATES INTRARENAL INFLAMMATION AFTER 12 MONTHS OF THERAPY IN LUPUS NEPHRITIS: INTERIM RESULTS FROM THE ReBioLup STUDY This interim analysis of the prospective ReBioLup cohort assessed the relationship between proteinuria and histological activity in lupus nephritis using protocol repeat kidney biopsies. Despite a moderate correlation (r=0.47), 19% of patients with minimal proteinuria had persistent intrarenal inflammation, and 73% of patients with high histological activity fulfilled criteria for complete clinical response. These findings challenge the use of proteinuria alone as a surrogate marker of renal remission. |
| Poster POS0125 | Thursday, 4 June 2026, 13:30 – 13:36 BST Basic Poster Tours: What’s up your SLEeve? Author: C Wincup (United Kingdom) Title: Mitochondrial Expansion and Interferon-Driven Bioenergetic Reprogramming Define CD4⁺ T Cell Dysfunction in Systemic Lupus Erythematosus This study investigates interferon-driven immunometabolic dysfunction in systemic lupus erythematosus (SLE), demonstrating that CD4⁺ T cells exhibit mitochondrial expansion, hypermetabolism, and impaired energetic efficiency. Using flow cytometry and Seahorse bioenergetic profiling, the authors show that IFN-α further amplifies metabolic stress in SLE T cells, supporting a role for chronic interferon-mediated metabolic rewiring in persistent immune activation and highlighting novel targets for immunometabolic therapy. |
| Oral OP0336 | Friday, 5 June 2026, 8:25 – 8:35 BST Basic Poster Tours: Clinical Abstract Sessions: Taming the wolf – new treatments in Systemic Lupus Author: R Furie (USA) Title: OBINUTUZUMAB INDUCES HISTOLOGICAL REMISSION AND DEEP KIDNEY PARENCHYMAL B-CELL DEPLETION IN PATIENTS WITH LUPUS NEPHRITIS: EXPLORATORY ANALYSES OF THE PHASE III REGENCY TRIAL This exploratory analysis from the Phase III REGENCY trial showed that obinutuzumab induced both histological remission and profound kidney tissue B-cell depletion in lupus nephritis. As the largest longitudinal kidney biopsy study conducted within a registrational lupus nephritis trial, it provides important mechanistic evidence linking targeted B-cell depletion to improved renal outcomes and offers new insights into the potential of tissue-level remission as a therapeutic goal. |
| Oral OP0341 | Friday, 5 June 2026, 9:15 – 9:25 BST Clinical Abstract Sessions: Taming the wolf – new treatments in Systemic Lupus Author: M Leandro (United Kingdom) Title: OBECABTAGENE AUTOLEUCEL (obe-cel), A CD19-TARGETING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS WITH SEVERE, REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (srSLE): INITIAL SAFETY, PRELIMINARY EFFICACY, PHARMACOKINETICS, AND BIOMARKER RESULTS FROM THE PHASE I CARLYSLE STUDY This Phase I CARLYSLE study evaluated obecabtagene autoleucel (obe-cel), a CD19-directed CAR-T cell therapy, in patients with severe refractory SLE. Treatment was associated with a favourable safety profile, clinically meaningful improvements in disease activity, and encouraging renal responses in lupus nephritis. With 83.3% of patients achieving DORIS remission and evidence of immune resetting following B-cell reconstitution, these findings further support the emerging role of CAR-T cell therapy in the treatment of SLE. |